Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

AbbVie’s upadacitinib holds potential to cement dominant place in alopecia areata with latest results, says GlobalData

AbbVie recently announced topline results from one of two parallel studies of the pivotal Phase III UP-AA trial evaluating upadacitinib in severe alopecia areata (AA). Upadacitinib’s latest results could provide AbbVie with a dominant place in AA while potentially addressing the need for treatment options with higher efficacy, according to GlobalData, a leading data and […]
Read more

Nanoscope Therapeutics’ MCO-010 holds potential to become new treatment option for retinitis, says GlobalData

Nanoscope Therapeutics has recently submitted a rolling biologics license application (BLA) to the FDA for MCO-010 (sonpiretigene isteparvovec), a novel gene therapy candidate targeting retinitis pigmentosa (RP). Currently, the RP treatment landscape includes only one FDA-approved therapy, Luxturna (voretigene neparvovec), which is indicated for a small subset of patients with biallelic RPE65 mutations. In contrast, […]
Read more

Unmet needs present persistent challenges for effective endometriosis treatment, says GlobalData

The endometriosis therapeutics market continues to face significant unmet needs, primarily due to low diagnosis rates, limited disease awareness, and a lack of well-tolerated, long-term treatment options. While surgical interventions can offer symptomatic relief, they are costly and do not guarantee long-term remission or prevention of recurrence. Moreover, patients often undergo multiple surgeries throughout their […]
Read more

Biomarker identification to address unmet needs of idiopathic pulmonary fibrosis treatment, says GlobalData

Idiopathic pulmonary fibrosis (IPF) is a progressive and often fatal lung disease characterized by the accumulation of scar tissue in the lungs, leading to respiratory failure. The current treatment approaches for IPF include Boehringer Ingelheim’s Ofev (nintedanib) and Roche’s Esbriet (pirfenidone). However, current treatments may not address several unmet needs in this space, particularly regarding […]
Read more

World Hepatitis Day 2025: Renewed global push urgent need amid rising mortality, says GlobalData

World Hepatitis Day, observed each year on 28 July, highlights the urgent need to combat viral hepatitis—one of the world’s deadliest infectious diseases, impacting over 300 million people globally. Despite available vaccines and treatments, rising mortality and persistent systemic, financial, and social barriers underscore the critical importance of renewed global efforts toward hepatitis elimination by […]
Read more

China’s obesity market poised for takeoff with homegrown therapies and late-stage pipeline, says GlobalData

China has recently approved the first locally developed obesity drug “Xinermei (mazdutide),” marking a critical milestone in the country’s obesity treatment landscape. Backed by a robust late-stage pipeline and differentiated dual-receptor mechanisms, the domestic obesity therapeutics market is set for rapid expansion, driven by innovation, rising disease burden, and a shift toward more accessible, locally […]
Read more

Diagnosed prevalent cases of HER2- breast cancer across 8MM set to reach 4.12 million in 2034, forecasts GlobalData

The burden of five-year diagnosed prevalent cases of HER2-Negative (HER2-) breast cancer is expected to increase at an annual growth rate (AGR) of 1.42% from around 3.61 million in 2024 to 4.12 million in 2034 across the eight major markets (8MM*), forecasts GlobalData, a leading data and analytics company. GlobalData’s latest report, “HER2-Negative Breast Cancer: […]
Read more

Semaglutide emerges as contender in cerebrovascular disease management, says GlobalData

Semaglutide, a GLP-1R agonist also known as Ozempic or Wegovy and initially developed for type 2 diabetes, is emerging as a promising candidate for neurological conditions. The recent clinical findings suggest its potential to improve outcomes in stroke and brain hemorrhage patients, driven by its cardiovascular and anti-inflammatory effects. These developments highlight a significant therapeutic […]
Read more

AP301 phase 3 trial highlights Alebund’s potential to differentiate in HP space, says GlobalData

Alebund Pharmaceuticals announced positive topline phase III results highlighting that the use of AP301 demonstrated a statistically significant and clinically meaningful improvement in serum phosphorus control in dialysis patients with hyperphosphatemia (HP). If approved, AP301 could potentially address two unmet needs in HP management: poor patient adherence and inadequate phosphorus control, says GlobalData, a leading […]
Read more

FDA approves 127 innovator and biosimilar drugs in 2024, marks shift in pharmaceutical approval landscape, says GlobalData

The US Food and Drug Administration (FDA) announced the approval of 127 innovator and biosimilar drugs in 2024, a notable decrease from the 149 approvals recorded in 2023. Despite the decline in overall approvals, the year saw a remarkable surge in innovative drug approvals, particularly from small pharmaceutical companies, many of which secured their first […]
Read more

Eli Lilly’s orforglipron and other key catalysts set to reshape drug landscape in Q3 2025, says GlobalData

Eli Lilly and Co’s orforglipron is emerging as a promising oral glucagon-like peptide (GLP)-1 therapy, with upcoming clinical milestones in obesity and diabetes set to shape its market trajectory. As a wave of key catalysts—including FDA decisions and late-stage trial results—approaches in Q3 2025, the pharmaceutical landscape is poised for shifts driven by innovation, competitive […]
Read more

Big Pharma prepare for next patent cliff as blockbuster drugs revenue losses loom, says GlobalData

The pharmaceutical industry is bracing for one of its most financially significant patent cliffs in over a decade, with multiple blockbuster drugs set to lose exclusivity by 2030. As biosimilars and generics flood the market, pricing pressures will intensify—particularly in oncology—challenging pharma companies to rethink revenue strategies, pipeline investments, and lifecycle management to safeguard long-term […]
Read more
1 … 7 8 9 10 11 … 110